PMVP PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezata…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 These Biotech Stocks Are Cheap Based On 1 Fundamental Measure Biotech stocks can offer high reward opportunities. Here are three North American biotech stocks that could offer both growth and value. | ||
 Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react? | ||
 PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer.Based on this data, the company announced its plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of the drug.Efficacy HighlightsThe interim data, gathered up to May 14, 2026, focus on patients with platinum-resistant or refractory ovarian cancer bearing the TP53 Y220C | ||
PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering PMV Pharmaceuticals (PMVP) said Monday that data from a phase 2 trial of rezatapopt showed a 46% ove | ||
 PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock? PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | ||